NCT06409767Recruiting
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation, a Multicenter Cluster Randomized Study
Source: ClinicalTrials.gov · Last updated 24 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in increased mortality. This encourages great alertness although not all patients require close monitoring. It is therefore critical to identify which patients are the most at risk for clinical deterioration to consider increased surveillance in these patients. The benefit of early intensive care unit (ICU) admission, as soon as the first signs of organ dysfunction appear, must also be clarified. Such an intervention could increase survival of patients by close monitoring and early initiation of organ-specific interventions but could also be responsible for anxiety and increased use of ICU resources. Many teams have analyzed the impact of early warning systems (EWS) including vital signs to detect organ dysfunction early on. It has been shown that these EWS could positively impact survival in many medical fields (pre-hospital, medicine or surgery departments). A few retrospective studies have explored the impact of EWS in hematology, with overall good prediction for ICU admission and mortality. Until now, it has however not been formally demonstrated that early ICU admission, as soon as the first signs of organ dysfunction appear, could benefit patients with hematologic malignancies. A randomized controlled trial studying the impact of early intervention would clarify the role of such a strategy. In this study, the investigators will prospectively evaluate the implementation of the National Early Warning Score (NEWS), with systematic referral to the ICU in high-score patients, to improve the survival of patients receiving intensive chemotherapy in ten academic centers. This score is one of the most performant and most frequently used to predict organ failure. Its calculation only requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. The investigators will therefore study the impact of ICU admission in patients with high NEWS in a randomized, controlled trial. A cluster randomization is planned in which the centers will be randomized between usual care (control group) and interventional care with transfer to the ICU in the event of a NEWS score ≥7 (interventional group). Each parameter used to calculate the NEWS will be collected at least three times a day by the attending nurse.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2224 (estimated)
- First submitted
- 7 May 2024
- Start date
- Apr 2025
- Primary completion date
- Apr 2028
- Lead sponsor
- University Hospital, Angers
- Diseases
- Multiple myeloma
- NCT number
- NCT06409767
What you commit to
- Study type: Interventional
- Planned participants: 2224
- From Apr 2025 to the primary completion date, Apr 2028
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hospitalization for Chimeric Antigenic Receptor (CAR) T-cell therapy
Other illness
- Person under forced psychiatric care
Other
- Decision of care limitation with decision not to transfer to ICU or not initiate organ support
- Pregnant, parturient or breastfeeding woman
- Person deprived of liberty by judicial or administrative decision
- Person under legal protection
- Person unable to express consent
Who the study is looking for
- Adult patient
- Hospitalization in a protected unit of a hematology department for induction therapy of acute myeloid leukemia or acute lymphoblastic leukemia induction, intensive chemotherapy with autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation
- Expected length of stay in the hematology department of at least 7 days
- Patient with social security
- Signed informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Amiens-Picardie Coordinator of this site? Confirm its status | Amiens | France | Recruiting |
| Centre Hospitalier Universitaire D'Angers Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| Centre Hospitalier Universitaire -Besançon Coordinator of this site? Confirm its status | Besançon | France | Recruiting |
| Centre Hospitalier Universitaire Brest Coordinator of this site? Confirm its status | Brest | France | Recruiting |
| Centre Hospitalier universitaire Nancy Coordinator of this site? Confirm its status | Nancy | France | Recruiting |
| Centre Hospitalier Universitaire Nantes Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
| Centre Hospitalier Universitaire poitiers Coordinator of this site? Confirm its status | Poitiers | France | Recruiting |
| centre Hospitalier Universitaire Saint etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Recruiting |
| centre Hospitalier Universitaire Strasbourg Coordinator of this site? Confirm its status | Strasbourg | France | Not yet recruiting |
| centre Hospitalier Universitaire Tours Coordinator of this site? Confirm its status | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.